Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Conditions
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Trial Timeline
Jul 6, 2023 → Oct 1, 2030
NCT ID
NCT05884255About Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide. is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Advanced Gastroenteropancreatic Neuroendocrine Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05884255. Target conditions include Advanced Gastroenteropancreatic Neuroendocrine Tumor.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Gastroenteropancreatic Neuroendocrine Tumor were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05884255 | Phase 3 | Recruiting |
Competing Products
20 competing products in Advanced Gastroenteropancreatic Neuroendocrine Tumor